$UNCY News

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story

UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval

UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15

B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target

Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Why Is Unicycive Therapeutics Stock Falling Tuesday?

Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor

Unicycive Therapeutics Files Base Prospectus For Offering Up To $150M Securities

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $18

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference